Q1 Earnings Estimate for Medpace Issued By Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Medpace in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Cherny forecasts that the company will earn $3.03 per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace’s Q2 2025 earnings at $2.96 EPS, Q3 2025 earnings at $2.92 EPS, Q4 2025 earnings at $3.16 EPS, FY2025 earnings at $12.07 EPS, FY2026 earnings at $12.76 EPS, FY2027 earnings at $13.90 EPS and FY2028 earnings at $15.81 EPS.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%.

Several other equities research analysts also recently issued reports on MEDP. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Leerink Partners assumed coverage on Medpace in a research report on Monday. They issued a “market perform” rating and a $330.00 price objective for the company. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Trading Down 0.3 %

Shares of Medpace stock opened at $316.61 on Wednesday. The stock’s fifty day simple moving average is $336.40 and its 200 day simple moving average is $339.26. The company has a market capitalization of $9.65 billion, a PE ratio of 25.07, a PEG ratio of 3.81 and a beta of 1.47. Medpace has a 12 month low of $302.01 and a 12 month high of $459.77.

Institutional Investors Weigh In On Medpace

Institutional investors have recently bought and sold shares of the company. Centaurus Financial Inc. raised its holdings in shares of Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares during the last quarter. Lindbrook Capital LLC grew its position in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares in the last quarter. HBK Sorce Advisory LLC increased its stake in Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. lifted its position in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after buying an additional 29 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in shares of Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock worth $243,000 after buying an additional 29 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.